| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/06/2002 | CN1080117C Treamtent of tumors with compounds having RXR retinoid receptor agonist activity |
| 03/06/2002 | CA2356797A1 Combination treatment for depression and anxiety |
| 03/06/2002 | CA2356557A1 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/06/2002 | CA2356545A1 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/05/2002 | US6353093 gidB |
| 03/05/2002 | US6353092 Patched-2 polypeptide |
| 03/05/2002 | US6353009 Method for the treatment and prevention of hyperuricemia |
| 03/05/2002 | US6353005 Treatment of gastrointestinal disorders |
| 03/05/2002 | US6353004 Peripherally acting anti-pruritic opiates |
| 03/05/2002 | US6352992 Endothelin antagonist and beta receptor blocking agent as combined preparations |
| 03/05/2002 | US6352984 For treatment of psychological disorders, schizophrenia |
| 03/05/2002 | US6352975 Methods of treating hypertension and compositions for use therein |
| 03/05/2002 | US6352970 Treatment of skeletal disorders |
| 03/05/2002 | US6352844 Ceramide generating retinoids and inhibitors of tumors |
| 03/05/2002 | US6352717 Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
| 03/05/2002 | US6352709 Introducing into patient a medical device of which at least a portion comprises one of a sydnonimine and a furoxan; anticoagulants |
| 03/05/2002 | US6352698 Free radical scavenger, antiallergen, and antiinflammatory agents |
| 03/05/2002 | CA2356553A1 Identification of a capacitative calcium channel in antigen presenting cells and uses thereof |
| 02/28/2002 | WO2002016937A1 Method of screening remedy for heart failure |
| 02/28/2002 | WO2002016638A1 METHOD FOR IDENTIFYING SUBSTANCES USEFUL FOR TREATING INFLAMMATION USING THE RESPONSE ELEMENT TO THE IλBα ROR RECEPTOR |
| 02/28/2002 | WO2002016636A2 Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders |
| 02/28/2002 | WO2002016632A1 Pharmaceutical compositions comprising a modulator of adamts-1 |
| 02/28/2002 | WO2002016615A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 02/28/2002 | WO2002016611A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 02/28/2002 | WO2002016602A2 Compositions and methods for the diagnosis and treatment of tumor |
| 02/28/2002 | WO2002016597A2 Lipid metabolism enzymes |
| 02/28/2002 | WO2002016587A2 Microtubule-associated proteins and tubulins |
| 02/28/2002 | WO2002016575A1 METHOD OF SCREENING FOR INHIBITORS OF HUMAN FATTY ACID-CoA LIGASE 4 |
| 02/28/2002 | WO2002016567A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/28/2002 | WO2002016553A2 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 02/28/2002 | WO2002016433A2 Two receptors of meiosis activating sterols designated sam1a and sam1b |
| 02/28/2002 | WO2002016417A2 Transgenic animal model for neurodegerative disease and uses thereof |
| 02/28/2002 | WO2002016416A2 Diagnosis and treatment of cardiovascular conditions |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016382A1 Improved specificity in treatment of diseases |
| 02/28/2002 | WO2002016381A2 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | WO2002016365A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity |
| 02/28/2002 | WO2002016309A1 Compounds and compositions for delivering active agents |
| 02/28/2002 | WO2002016235A1 Spray device |
| 02/28/2002 | WO2002015977A2 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | WO2002015959A2 Compounds and compositions for delivering active agents |
| 02/28/2002 | WO2002015942A1 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 02/28/2002 | WO2002015941A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015932A1 Methods for treating demyelinating diseases |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015918A2 Method and compositions for promoting osteogenesis |
| 02/28/2002 | WO2002015909A1 Substituted piperidines as melanocortin receptor agonists |
| 02/28/2002 | WO2002015905A1 The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity |
| 02/28/2002 | WO2002015900A1 Ibuprofen solutions for capsule-filling and capsule prepartions |
| 02/28/2002 | WO2002015899A1 Combination therapy for the treatment of migraine |
| 02/28/2002 | WO2002015896A2 Methods and compositions for potentiating antibiotic action against persistent/tolerant pathogenic microorganisms |
| 02/28/2002 | WO2002015895A2 Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| 02/28/2002 | WO2002015894A2 Use of vitamin d derivatives as bone resorption inhibitors |
| 02/28/2002 | WO2002015893A2 Treatment of wounds |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015891A2 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015884A2 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015881A2 Use of a porous carrier |
| 02/28/2002 | WO2002015845A2 Anti-hypercholesterolemic drug combination |
| 02/28/2002 | WO2002015832A1 Non-hormonal vaginal contraceptive |
| 02/28/2002 | WO2002015809A2 Dental composition for hypersensitive teeth |
| 02/28/2002 | WO2002015722A2 Treatment of helicobacter with isothiocyanates |
| 02/28/2002 | WO2002015680A1 Type iii allergic inflammation model animal |
| 02/28/2002 | WO2002009667A9 Dispersions for formulating slightly or poorly soluble active ingredients |
| 02/28/2002 | WO2002000269A8 The use of honey in wound dressings |
| 02/28/2002 | WO2001095924A3 Method for treating a movement disorder |
| 02/28/2002 | WO2001087887A3 Neuroprotective and anti-proliferative compounds |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085699A3 Prodrugs of hiv replication inhibiting pyrimidines |
| 02/28/2002 | WO2001085196A3 Cxcr4 antagonist treatment of hematopoietic cells |
| 02/28/2002 | WO2001081343A3 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 02/28/2002 | WO2001080713A3 Methods for non-permanent occlusion of a uterine artery |
| 02/28/2002 | WO2001076615A3 Cxcr4 agonist treatment of hematopoietic cells |
| 02/28/2002 | WO2001075064A3 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 02/28/2002 | WO2001073029A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/28/2002 | WO2001072281A3 Microspheres for active embolization |
| 02/28/2002 | WO2001070255A3 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 02/28/2002 | WO2001068852A3 Apolipoprotein-a-i regulation of t-cell signalling |
| 02/28/2002 | WO2001053339A3 Egg specific surface proteins |
| 02/28/2002 | WO2001053321A3 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001045685A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001042474A3 Interferon-like molecules and uses thereof |
| 02/28/2002 | WO2001041769A3 Combination of cyamemazine and an atypical neuroleptic |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001027261A3 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000078328A3 USE OF GROWTH HORMONE (hGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES |
| 02/28/2002 | WO2000077037A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/28/2002 | US20020026176 Devices for intraocular drug delivery |
| 02/28/2002 | US20020025981 Synergistic mixture of amlodipine and statins |
| 02/28/2002 | US20020025952 Combinations of statins, estrogens and estrogenic agents |
| 02/28/2002 | US20020025950 Anticarcinogenic agents |